Neurology · North Carolina
Neurology studies in North Carolina
100 studies have at least one recruiting site in North Carolina. Neurology research spans migraine, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, epilepsy, stroke and nerve pain.
100 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 2/Phase 3
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Janssen Research & Development, LLC
- Location
- Charlotte, NC + 11 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)
Sundance Biosciences, Inc.
- Location
- Raleigh, NC + 2 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Pfizer
- Location
- Charlotte, NC + 69 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
Pfizer
- Location
- Charlotte, NC + 54 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Location
- Greensboro, NC + 43 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 3
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
Novartis Pharmaceuticals
- Location
- Chapel Hill, NC + 39 other US sites
- Eligibility basics
- Ages 21–70
- RecruitingPhase 2/Phase 3
A Study of Buntanetap in Participants With PD
Annovis Bio Inc.
- Location
- Durham, NC + 26 other US sites
- Eligibility basics
- Ages 40–85
- RecruitingPhase 1/Phase 2
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
Tr1X, Inc.
- Location
- Durham, NC + 7 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
Epygenix
- Location
- Durham, NC + 16 other US sites
- Eligibility basics
- Ages 2+
- RecruitingPhase 3
Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
Pharmazz, Inc.
- Location
- Greensboro, NC + 13 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie
- Location
- Charlotte, NC + 87 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
Dompé Farmaceutici S.p.A
- Location
- Durham, NC + 13 other US sites
- Eligibility basics
- Ages 50–80
- RecruitingPhase 1/Phase 2
ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome
Ionis Pharmaceuticals, Inc.
- Location
- Durham, NC + 4 other US sites
- Eligibility basics
- Ages 2–12
- Recruiting
Evaluating the Efficacy of Perinatal Membrane Allografts in Addition to the Standard of Care for the Treatment of Non-healing Diabetic Foot Ulcers.
Samaritan Biologics
- Location
- Monroe, NC
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
Zydus Therapeutics Inc.
- Location
- Winston-Salem, NC + 13 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
A Pivotal Clinical Study to Evaluate the MySalvia System for the Treatment of Resistant Migraine
Salvia BioElectronics
- Location
- Charlotte, NC + 2 other US sites
- Eligibility basics
- Ages 22–84
- RecruitingPhase 3
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Novartis Pharmaceuticals
- Location
- Raleigh, NC + 42 other US sites
- Eligibility basics
- Ages 40–70
- Recruiting
CAPTURE-2: Controlled Arterial Protection to Ultimately Remove Embolic Material
EmStop Inc
- Location
- Asheville, NC + 6 other US sites
- Eligibility basics
- Ages 22+
- RecruitingPhase 1
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
Eli Lilly and Company
- Location
- Durham, NC + 4 other US sites
- Eligibility basics
- Ages 50–85
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
Kallyope Inc.
- Location
- Charlotte, NC + 111 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Eidos Therapeutics, a BridgeBio company
- Location
- Durham, NC + 39 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
BlueRock Therapeutics
- Location
- Durham, NC + 33 other US sites
- Eligibility basics
- Ages 45–75
- Recruiting
GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study
W.L.Gore & Associates
- Location
- Charlotte, NC + 30 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated
- Location
- Asheville, NC + 69 other US sites
- Eligibility basics
- Ages 18–80
Who these studies look for
Most require a confirmed diagnosis; memory studies often ask for a study partner who knows you well to attend some visits.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.
Questions
Why do memory studies need a study partner?
A partner can report day-to-day changes the participant may not notice. Each study explains what the partner is asked to do.